BR0316238A - Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer - Google Patents

Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer

Info

Publication number
BR0316238A
BR0316238A BR0316238-9A BR0316238A BR0316238A BR 0316238 A BR0316238 A BR 0316238A BR 0316238 A BR0316238 A BR 0316238A BR 0316238 A BR0316238 A BR 0316238A
Authority
BR
Brazil
Prior art keywords
mek
inhibitor
capecitabine
cancer treatment
combination chemotherapy
Prior art date
Application number
BR0316238-9A
Other languages
English (en)
Inventor
Ronald Lynn Merriman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0316238A publication Critical patent/BR0316238A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

"QUIMIOTERAPIA DE ASSOCIAçãO COMPREENDENDO UM INIBIDOR DE MEK E CAPECITABINA PARA TRATAMENTO DE CâNCER". A presente invenção refere-se a com um método para tratar câncer utilizando uma associação de agentes oncolíticos conhecidos. Especificamente, esta invenção refere-se a um método para tratar câncer utilizando uma associação de um inibidor da MEK e capecitabina.
BR0316238-9A 2002-11-15 2003-11-03 Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer BR0316238A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42671702P 2002-11-15 2002-11-15
PCT/IB2003/004936 WO2004045617A1 (en) 2002-11-15 2003-11-03 Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer

Publications (1)

Publication Number Publication Date
BR0316238A true BR0316238A (pt) 2005-10-11

Family

ID=32326406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316238-9A BR0316238A (pt) 2002-11-15 2003-11-03 Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer

Country Status (9)

Country Link
US (1) US20040147478A1 (pt)
EP (1) EP1562601A1 (pt)
JP (1) JP2006508974A (pt)
AU (1) AU2003274576A1 (pt)
BR (1) BR0316238A (pt)
CA (1) CA2506085A1 (pt)
MX (1) MXPA05003431A (pt)
TW (1) TW200412937A (pt)
WO (1) WO2004045617A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101013932B1 (ko) * 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
ES2557316T3 (es) 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
KR20120111739A (ko) 2009-12-31 2012-10-10 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) 키나제 억제제로서의 사용을 위한 삼환식 화합물
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
JP6182456B2 (ja) 2010-12-22 2017-08-23 フェイト セラピューティクス，インコーポレイテッド 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
DK2710018T3 (da) 2011-05-19 2022-03-21 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Makrocykliske forbindelser som proteinkinasehæmmere
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
ES2708669T3 (es) 2011-08-01 2019-04-10 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK
US20140309183A1 (en) * 2011-08-24 2014-10-16 David Kerr Low-Dose Combination Chemotherapy
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
WO2015085097A1 (en) 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
CA2941004A1 (en) 2014-03-04 2015-09-11 Peter Flynn Improved reprogramming methods and cell culture platforms
RU2733735C2 (ru) 2014-07-15 2020-10-06 Дженентек, Инк. Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek
EP3362570A4 (en) 2015-10-16 2019-03-20 Fate Therapeutics, Inc. PLATFORM FOR INDUCTION AND MAINTENANCE OF PLURIPOTENCE IN THE FUNDAMENTAL STATE
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CA3090748A1 (en) * 2018-02-12 2019-08-15 Array Biopharma Inc. Methods and combination therapy to treat biliary tract cancer
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
JP2002525320A (ja) * 1998-09-25 2002-08-13 ワーナー−ランバート・カンパニー アセチルジナリンとジェムシタビン、キャペシタビンまたはシスプラチンの組み合わせによる癌の化学療法
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
BR9916735A (pt) * 1998-12-31 2001-09-25 Sugen Inc Compostos de 3-heteroarilidenil-2-indolinona para a modulação da atividade das cinases protéicas e para uso na quimioterapia do cancêr
EA005818B1 (ru) * 2000-07-19 2005-06-30 Уорнер-Ламберт Компани Сложные эфиры фениламинобензгидроксамовых кислот
CA2483627A1 (en) * 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Also Published As

Publication number Publication date
JP2006508974A (ja) 2006-03-16
MXPA05003431A (es) 2005-07-05
CA2506085A1 (en) 2004-06-03
TW200412937A (en) 2004-08-01
AU2003274576A1 (en) 2004-06-15
US20040147478A1 (en) 2004-07-29
WO2004045617A1 (en) 2004-06-03
EP1562601A1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
PT1297851E (pt) Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
ATE408601T1 (de) Fredericamycin-derivate
BRPI0411239A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer inibição de canal de potássio, e, uso de um composto
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
BR0314196A (pt) Inibidores de tgf-beta
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
WO2004012746A3 (en) New uses for inhibitors of inosine monophosphate dehydrogenase
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.